Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug Ampyra. First the stock went higher, but started falling when investors realized that sales will drop ...
EXITING ACOR WITH PROFIT RIGHT HERE AT $32.61.
Our negative thesis on Acordia Therapeutics (ACOR) has not changed. However we are positive on the group, therefore we will exit the entire position right here and plan to short again on spikes up. For ...
ADDING TO $ACOR (ACORDA THERAPEUTICS) SHORT SALE POSITION HERE AT $38.15
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
AS PER PRIOR POST, ADDING TO $ACOR (ACORDIA) SHORT AT $33.37
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
UPDATE ON OPEN INDIVIDUAL STOCK POSITIONS
We are exiting $BCRX and $AVAV; please see separate posts for the reasons.We are short on $ACOR with average price of $30.28. Our thesis has not changed in that Ampyra is not a very good ...
WOW! FDA AGREES WITH OUR LONGSTANDING ASSESSMENT OF FAMPRIDINE-SR , SHORT SELL $ACOR (ACORDIA) PER OUR PRIOR POST
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED
The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR's Fampridine-SR for improvement of walking in patients with multiple sclerosis .We have been negative on ACOR from the very beginning ...
CHECK OUR PERFORMANCE
